Study of Decitabine in Preventing Tumor Growth
Study of Decitabine in Preventing Tumor Growth
Background:
In preclinical studies, we have demonstrated induction of tumor antigen and tumor
suppressor gene expression in lung and esophageal cancer cells as well as malignant
pleural mesothelioma cells following DNA hypomethylation using decitabine concentrations
which are potentially achievable in clinical settings. In order to assess the feasibility
of DNA hypomethylation in solid tumors, patients with inoperable thoracic malignancies
will receive two cycles of 72-hour intravenous infusion of decitabine using a phase
I study design.
Location and Contact Information:
Maryland
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, 20892,
United States;
Recruiting
Clinical Studies Support Center/NCI 1-888-624-1937
ncicssc@mail.nih.gov
